Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)GlobeNewsWire • 05/24/22
Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative ColitisGlobeNewsWire • 05/18/22
Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel DiseGlobeNewsWire • 05/16/22
Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingGlobeNewsWire • 05/02/22
Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research PipelineGlobeNewsWire • 01/10/22
Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/05/22
Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver DiseasesGlobeNewsWire • 11/15/21
Surrozen's Inflammatory Bowel Disease Candidate Shows Encouraging Preclinical ActionBenzinga • 10/06/21
Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology WeekGlobeNewsWire • 10/05/21
Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human ResourcesGlobeNewsWire • 09/23/21
Surrozen Debuts as Publicly Traded Leader in Wnt Biology and Tissue RegenerationBusiness Wire • 08/11/21